Raymond James cuts Delek US stock price target on valuation review

Raymond James cut its Delek US price target to $95 from $100 but maintained an Outperform rating, citing operational progress, favorable small-refinery-exemption grants, and potential value-enhancing initiatives; it expects elevated volatility to persist. Separately, Delek reported Q3 2026 adjusted EPS of $10.53 versus $7.64 expected and revenue of $4.39B versus $3.75B expected, expects $425M in exemption proceeds in Q4, and raised its quarterly dividend 18% to $0.30 per share.

Analysis

The key underwriting distinction is cash quality: SRE proceeds can support near-term liquidity and capital returns, but should not be capitalized like recurring refining earnings. The larger upside case depends on whether operating improvements and midstream optimization lift through-cycle cash generation and whether management converts the sum-of-the-parts narrative into observable value realization. A higher dividend may attract income buyers, but it also raises the bar for sustaining distributions if refining margins normalize.

Near term, the sharp weekly drawdown after a strong year makes positioning and refinery-cycle exposure more important than the analyst target. Over 1–3 months, verify receipt and timing of the expected exemption proceeds, cash conversion against reported earnings, and evidence that savings are recurring rather than timing or market effects. Over 6–18 months, the discount can persist unless asset-level disclosures, a transaction, or disciplined capital allocation make the midstream value legible. A reversal in crack spreads, adverse crude differentials, weaker product demand, or regulatory changes affecting small-refinery exemptions would pressure both earnings and the rerating thesis. The contrarian risk is that investors may be treating a cyclical earnings peak and one-off proceeds as durable; equally, a pullback may overstate that risk if operational delivery persists. The price-target cut alongside an Outperform rating is not independent proof of undervaluation.

Key Decisions for Investors

• Avoid chasing the analyst upgrade narrative; consider a staged long in DK only after price action stabilizes and refining indicators confirm the recent earnings strength is not solely a favorable-cycle spike. Define the thesis around cash generation and operational delivery, not the target price.
• Treat the expected SRE proceeds as a near-term catalyst, not a recurring valuation multiple: verify actual receipt, use of proceeds, and whether distributions remain covered by normalized free cash flow before extrapolating the dividend increase.
• Track quarterly refining margins, cash conversion, and quantified savings, plus any concrete midstream monetization or restructuring action. Failure to show recurring savings or progress on value realization over the next several quarters would weaken the rerating case.
• Falsifiers: a material decline in refining margins or unfavorable crude differentials, a delayed or reduced exemption payment, lower distribution coverage, or guidance that shows operating improvements are not recurring. These would favor reducing exposure rather than averaging down.